Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199


Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening.

Tournier N, Valette H, Peyronneau MA, Saba W, Goutal S, Kuhnast B, Dollé F, Scherrmann JM, Cisternino S, Bottlaender M.

J Nucl Med. 2011 Mar;52(3):415-23. doi: 10.2967/jnumed.110.079608. Epub 2011 Feb 14.


(R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.

Römermann K, Wanek T, Bankstahl M, Bankstahl JP, Fedrowitz M, Müller M, Löscher W, Kuntner C, Langer O.

Nucl Med Biol. 2013 Oct;40(7):873-8. doi: 10.1016/j.nucmedbio.2013.05.012. Epub 2013 Jul 8.


Avoiding barriers to PET radioligand development: cellular assays of brain efflux transporters.

Hall MD, Pike VW.

J Nucl Med. 2011 Mar;52(3):338-40. doi: 10.2967/jnumed.110.081125. Epub 2011 Feb 14. No abstract available.


Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier.

Poller B, Drewe J, Krähenbühl S, Huwyler J, Gutmann H.

Cell Mol Neurobiol. 2010 Jan;30(1):63-70. doi: 10.1007/s10571-009-9431-1. Epub 2009 Jul 23.


[¹¹C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats.

Hosten B, Boisgard R, Jacob A, Goutal S, Saubaméa B, Dollé F, Scherrmann JM, Cisternino S, Tournier N.

Eur J Pharm Sci. 2013 Nov 20;50(3-4):520-5. doi: 10.1016/j.ejps.2013.08.015. Epub 2013 Aug 24.


P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

Durmus S, Xu N, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH.

Pharmacol Res. 2013 Oct;76:9-16. doi: 10.1016/j.phrs.2013.06.009. Epub 2013 Jul 1.


Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.

Kodaira H, Kusuhara H, Ushiki J, Fuse E, Sugiyama Y.

J Pharmacol Exp Ther. 2010 Jun;333(3):788-96. doi: 10.1124/jpet.109.162321. Epub 2010 Mar 19.


PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.

Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.

Nucl Med Biol. 2015 Nov;42(11):833-41. doi: 10.1016/j.nucmedbio.2015.07.004. Epub 2015 Jul 15.


[(18)F]FDG is not transported by P-glycoprotein and breast cancer resistance protein at the rodent blood-brain barrier.

Wanek T, Traxl A, Bankstahl JP, Bankstahl M, Sauberer M, Langer O, Kuntner C.

Nucl Med Biol. 2015 Jul;42(7):585-9. doi: 10.1016/j.nucmedbio.2015.03.004. Epub 2015 Mar 18.


Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.

Poller B, Wagenaar E, Tang SC, Schinkel AH.

Mol Pharm. 2011 Apr 4;8(2):571-82. doi: 10.1021/mp1003898. Epub 2011 Mar 4.


A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.

Graber-Maier A, Gutmann H, Drewe J.

Mol Pharm. 2010 Oct 4;7(5):1618-28. doi: 10.1021/mp100040f. Epub 2010 Aug 11.


High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.

Karlsson JE, Heddle C, Rozkov A, Rotticci-Mulder J, Tuvesson O, Hilgendorf C, Andersson TB.

Drug Metab Dispos. 2010 Apr;38(4):705-14. doi: 10.1124/dmd.109.028886. Epub 2010 Jan 13.


Role of Human Breast Cancer Related Protein versus P-Glycoprotein as an Efflux Transporter for Benzylpenicillin: Potential Importance at the Blood-Brain Barrier.

Li Y, Wu Q, Li C, Liu L, Du K, Shen J, Wu Y, Zhao X, Zhao M, Bao L, Gao J, Keep RF, Xiang J.

PLoS One. 2016 Jun 14;11(6):e0157576. doi: 10.1371/journal.pone.0157576. eCollection 2016.


An electrically tight in vitro blood-brain barrier model displays net brain-to-blood efflux of substrates for the ABC transporters, P-gp, Bcrp and Mrp-1.

Helms HC, Hersom M, Kuhlmann LB, Badolo L, Nielsen CU, Brodin B.

AAPS J. 2014 Sep;16(5):1046-55. doi: 10.1208/s12248-014-9628-1. Epub 2014 Jun 17.


Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).

Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Declèves X.

Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4.


The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).

Römermann K, Helmer R, Löscher W.

Neuropharmacology. 2015 Jun;93:7-14. doi: 10.1016/j.neuropharm.2015.01.015. Epub 2015 Jan 31.


Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of 99mTechnetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2.

Cattelotte J, Tournier N, Rizzo-Padoin N, Schinkel AH, Scherrmann JM, Cisternino S.

J Neurochem. 2009 Feb;108(3):767-75. doi: 10.1111/j.1471-4159.2008.05832.x. Epub 2008 Dec 4.


In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.

Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O, Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3307-13.

Supplemental Content

Support Center